As per the research report, the size of the Middle East and Africa Rubella Vaccine (Human Diploid Cell) market was valued at USD XX billion in 2023 and is expected to reach USD XX billion by 2028 at XX % CAGR during the forecast period 2023 to 2028.
The increased incidence of rubella infection results in a congenital disability known as congenital rubella syndrome (CRS), affecting the infant mortality rate. This is a severe issue that plays a massive role in the growth of the MEA rubella vaccine market. The high awareness of air pollution and hygiene to prevent the spread of germs to a large population in developing and underdeveloped countries is also driving the market. Testing for measles, mumps, rubella, and chickenpox among hospital staff is mandatory to detect those who are susceptible to infections and need to be vaccinated, and thus prevent transmission of these infections to colleagues or patients.
Many local government authorities are focusing on increasing the production of rubella vaccines with fewer side effects and more effectiveness. In addition, the efforts of vaccine manufacturers to partner with government organizations to improve the vaccination drive and eliminate the rubella infection rate will positively impact the market. For instance, in Saudi Arabia, the Ministry of Health reports that the decreased annual incidence of rubella was more minor than 1/100,000 population.
These numbers suggest the driving force behind the awareness and campaign in the MEA region. This is supported by government funds for R&D activities on vaccines and better health education for the population.
However, some of the factors anticipated to hampering the growth of the MEA rubella vaccine market are rare cases of allergic reaction associated with the rubella vaccine, lack of awareness among people in underdeveloped regions, and inadequate supply of vaccines due to poor healthcare infrastructure.
This research report on the MEA Rubella Vaccine Market has been segmented and sub-segmented into the following categories.
By End User:
By Country:
Geographically, the MEA Rubella Vaccine Market will continue to grow significantly in the years to come due to the raising awareness, supportive governments, and camps to limit the infection rate and its complications.
The UAE rubella vaccine market is anticipated to reach a decent CAGR due to the increasing number of government-run free vaccination programs; this will drive the market's growth.
The Saudi Arabia rubella vaccine market will grow at a high CAGR owing to the strict implementation of vaccination for school-going children and the growing population.
The South African rubella vaccine market will have a steady CAGR during the forecast period. This is because this region has a high infection rate and growing awareness. The rubella virus circulates widely in Africa, mainly in children under 15, and about 5% of cases occur in those over 15 years old.
KEY MARKET PLAYERS
The leading companies dominating the MEA Rubella Vaccine Market profiled in the report are Merck & Co., Inc., GlaxoSmithKline Plc, Chiron Corporation (Novartis), and Sanofi-Aventis, Serum Institute of India, Astellas Pharma Inc., AstraZeneca Plc. (Medimmune, LLC.), CSL Limited, Pfizer Inc., and Berna Biotech (Crucell).,
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region